November 1, 2017 / 6:11 AM / 2 months ago

BRIEF-Cosmo Pharmaceuticals: update on commercialization of Rifamycin SV MMX

Nov 1 (Reuters) - COSMO PHARMACEUTICALS NV:

* UPDATE ON COMMERCIALIZATION OF RIFAMYCIN SV MMX(R)

* ‍ITS PARTNER DR. FALK PHARMA HAS FILED FOR MARKETING AUTHORIZATION OF RIFAFALK 200MG IN GERMANY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below